Egetis Therapeutics AB (EGTX) Stock Price & Analysis

1 Followers

EGTX Stock Chart & Stats

kr 11.12kr 0.00(0.00%)

At close: Nov 12 5:30 PM GMT+1

Day’s Range: SEK 11.10 - SEK 11.14
52-Week Range: SEK 3.63 - SEK 11.18
Previous Close: SEK 11.12
Volume: N/A
Average Volume (3M): 3.93M
Market Cap: SEK 5.17B
Enterprise Value: SEK 3.93B
Total Cash (Recent Filing): SEK 378.40M
Total Debt (Recent Filing): SEK 68.80M
Price to Earnings (P/E): ―
Beta: -0.31
Next Earnings: Feb 25, 2027 (Est.)
EPS Estimate: -0.11
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue growth shows increasing commercial traction for the company’s rare-disease portfolio and provides a larger base from which future products can scale. Continued top-line expansion could improve operating leverage over time if development and commercialization costs grow more slowly than sales.

Moderate Leverage

Moderate leverage and a substantial equity base provide greater financial resilience than a highly debt-funded structure. This can preserve flexibility to support late-stage development and commercialization while limiting the immediate burden of debt servicing on scarce cash resources.

Gross Margin Recovery

The return to a positive gross margin indicates that underlying product economics have improved from earlier periods. Although the margin remains modest, further improvement could strengthen the contribution from commercial revenue and gradually reduce the gap between sales and operating costs.

Bears Say

Deep Operating Losses

Costs remain far above the current revenue base, leaving the company without meaningful operating profitability despite improved sales. Persistent losses reduce internal funding capacity and make eventual earnings improvement dependent on substantial revenue growth, cost control, or additional financing.

Sustained Cash Burn

Large negative operating and free cash flow means ongoing development and commercial activities consume substantial cash rather than generating it. This weakens financial self-sufficiency and can require external funding, potentially constraining investment choices or diluting existing shareholders.

Capital Base Erosion Risk

Deeply negative returns on equity show that the existing capital base is not currently producing economic returns. If losses persist, accumulated deficits can weaken financial flexibility over time, increasing the importance of successful commercialization or new funding to sustain operations.

Egetis Therapeutics AB News

Egetis downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Egetis Therapeutics (PDPHF) to Neutral from Overweight with a price target of SEK 11.25, down from SEK 33. Published first on TheFly – the ultimate source for

1w agoP0F PDPHF

Egetis Wins U.S. Approval for EMCITATE and Agrees $190 Million PRV Sale

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an announcement. Egetis Therapeutics, a rare-disease pharmaceutical company focused on thyroid disorders, reported rising EMCITATE revenue and expanded its commercial presence during

1w agoP0F PDPHF

Egetis Board Recommends ANI’s SEK 5.3 Billion Cash Offer

The latest update is out from Egetis Therapeutics AB ( ($SE:EGTX) ). Egetis Therapeutics’ board unanimously recommends ANI Pharmaceuticals’ public cash offer, valuing the company at approximately SEK 5.3 billion.

1w agoP0F PDPHF

P0F Upcoming Earnings Report: What to Expect?

Egetis Therapeutics AB (P0F) is scheduled to report 3rd quarter earnings on 11/06/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Egetis Therapeutics AB to post earnings

1w agoP0F PDPHF

Egetis to Sell Priority Review Voucher for $190 Million

Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an update. Egetis Therapeutics and wholly owned subsidiary Rare Thyroid Therapeutics International agreed to sell the company’s Rare Pediatric Disease Priority Review

1w agoP0F PDPHF

Egetis Therapeutics Launches First FDA-Approved EMCITATE Therapy for MCT8 Deficiency in U.S.

Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an update. Egetis Therapeutics has launched EMCITATE in the United States for adults and pediatric patients with MCT8 deficiency, making available the

2w agoP0F PDPHF

Egetis Therapeutics Sets Nomination Committee for 2027 AGM

Egetis Therapeutics AB ( ($SE:EGTX) ) has provided an announcement. Egetis Therapeutics AB has appointed the members of its Nomination Committee ahead of the 2027 Annual General Meeting scheduled for

3w agoP0F PDPHF

Egetis bolsters tiratricol case with largest RTH-beta cohort study

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an update. Egetis Therapeutics has highlighted new clinical evidence for its thyroid hormone analogue tiratricol, following publication in eBioMedicine of the largest

3w agoP0F PDPHF

Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an announcement. Egetis Therapeutics has reported changes in the composition of its share and vote structure for September following the exercise of

1M agoP0F PDPHF

Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE

Egetis Therapeutics AB ( ($SE:EGTX) ) just unveiled an update. Egetis Therapeutics has received U.S. FDA approval for EMCITATE (tiratricol), the first and only treatment in the United States for

1M agoP0F PDPHF

Egetis to Present New Emcitate Data at Major European Endocrinology Meetings

Egetis Therapeutics AB ( ($SE:EGTX) ) has issued an update. Egetis Therapeutics will showcase new clinical data for Emcitate, its thyroid hormone analogue tiratricol for MCT8 deficiency, at two major

2M agoP0F PDPHF

Egetis Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Egetis Therapeutics (PDPHF) with an Overweight rating and SEK 23 price target Published first on TheFly – the ultimate source for real-time,

4M agoP0F PDPHF

EGTX FAQ

What was Egetis Therapeutics AB’s price range in the past 12 months?

Egetis Therapeutics AB lowest stock price was kr 3.63 and its highest was kr 11.18 in the past 12 months.

What is Egetis Therapeutics AB’s market cap?

Egetis Therapeutics AB’s market cap is kr 5.17B.

When is Egetis Therapeutics AB’s upcoming earnings report date?

Egetis Therapeutics AB’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 104 days.

How were Egetis Therapeutics AB’s earnings last quarter?

Egetis Therapeutics AB released its earnings results on Nov 06, 2026. The company reported -kr 0.197 earnings per share for the quarter.

Is Egetis Therapeutics AB overvalued?

According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.

Does Egetis Therapeutics AB pay dividends?

Egetis Therapeutics AB does not currently pay dividends.

What is Egetis Therapeutics AB’s EPS estimate?

Egetis Therapeutics AB’s EPS estimate is -0.11.

How many shares outstanding does Egetis Therapeutics AB have?

Egetis Therapeutics AB has 464,965,580 shares outstanding.

What happened to Egetis Therapeutics AB’s price movement after its last earnings report?

Egetis Therapeutics AB reported an EPS of -kr 0.197 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Egetis Therapeutics AB?

Currently, no hedge funds are holding shares in SE:EGTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Egetis Therapeutics AB

Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.

Egetis Therapeutics AB (EGTX) Earnings & Revenues

Historic Earnings Reports

EGTX Stock 12 Month Forecast

Average Price Target

kr 11.25▲(1.17% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

Highkr 11.25

Averagekr 11.25

Lowkr 11.25

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Ownership Overview

0.09% Mutual Funds
99.68% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

EGTX Stock Chart & Stats

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Moderate Leverage

Gross Margin Recovery

Bears Say

Deep Operating Losses

Sustained Cash Burn

Capital Base Erosion Risk

Egetis Therapeutics AB News

Egetis downgraded to Neutral from Overweight at Cantor Fitzgerald

Egetis Wins U.S. Approval for EMCITATE and Agrees $190 Million PRV Sale

Egetis Board Recommends ANI’s SEK 5.3 Billion Cash Offer

P0F Upcoming Earnings Report: What to Expect?

Egetis to Sell Priority Review Voucher for $190 Million

Egetis Therapeutics Launches First FDA-Approved EMCITATE Therapy for MCT8 Deficiency in U.S.

Egetis Therapeutics Sets Nomination Committee for 2027 AGM

Egetis bolsters tiratricol case with largest RTH-beta cohort study

Egetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise

Egetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE

Egetis to Present New Emcitate Data at Major European Endocrinology Meetings

Egetis Therapeutics initiated with an Overweight at Cantor Fitzgerald

EGTX FAQ

Company Description

Egetis Therapeutics AB

Egetis Therapeutics AB (EGTX) Earnings & Revenues

EGTX Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium